NCT06276088
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy
StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2024); last known: Recruiting
- Minor Site contacts updated at 1 of 5 sitesv3
- Minor Study title shortened, about 5 wordsv2
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Incidence of hyperprogression
Timeframe: 2 years
Secondary (3)
Event-free survival
Progression-free survival
Overall survival
Sites
5 sites in 1 country